[1] Nelson P T, Alafuzoff I, Bigio E H, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature[J]. J Neuropathol Exp Neurol, 2012, 71(5): 362-381. [2] Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes[J]. Nat Neurosci, 2012, 15(3): 349-357. [3] Ke P C, Zhou R H, Serpell L C, et al. Half a century of amyloids: past, present and future[J]. Chem Soc Rev, 2020, 49(15): 5473-5509. [4] Selkoe D J. Biology of β-amyloid precursor protein and the mechanism of Alzheimer disease[M] //Terry R D. Alzheimer Disease. Philadelphia: Lippincott Williams & Wilkins, 1999: 293-310. [5] Haass C, Kaether C, Thinakaran G, et al. Trafficking and proteolytic processing of APP[J]. Cold Spring Harb Perspect Med, 2012, 2(5): a006270. [6] Braak H, Thal D R, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years[J]. J Neuropathol Exp Neurol, 2011, 70(11): 960-969. [7] Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view[J]. J Neuropathol Exp Neurol, 2003, 62(9): 885-898. [8] Greenberg S M, Bacskai B J, Hernandez-Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer disease-one peptide, two pathways[J]. Nat Rev Neurol, 2020, 16(1): 30-42. [9] Revesz T, Holton J L, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies[J]. Acta Neuropathol, 2009, 118(1): 115-130. [10] Oakley H, Cole S L, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation[J]. J Neurosci, 2006, 26(40): 10129-10140. [11] Jawhar S, Trawicka A, Jenneckens C, et al. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5xFAD mouse model of Alzheimer's disease[J]. Neurobiol Aging, 2012, 33(1): 196.e29-196.e40. [12] Richard B C, Kurdakova A, Baches S, et al. Gene dosage dependent aggravation of the neurological phenotype in the 5xFAD mouse model of Alzheimer's disease[J]. J Alzheimers Dis, 2015, 45(4): 1223-1236. [13] Giannoni P, Arango-Lievano M, Neves I D, et al. Cerebrovascular pathology during the progression of experimental Alzheimer's disease[J]. Neurobiol Dis, 2016, 88: 107-117. [14] Wisniewski H M, Bancher C, Barcikowska M, et al. Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease[J]. Acta Neuropathol, 1989, 78(4): 337-347. [15] Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms[J]. Acta Neuropathol, 2005, 110(4): 345-359. [16] Attems J, Jellinger K A. The overlap between vascular disease and Alzheimer's disease-lessons from pathology[J]. BMC Med, 2014, 12: 206. [17] Kapasi A, Schneider J A. Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons[J]. Biochim Biophys Acta, 2016, 1862(5): 878-886. [18] Vinters H V. Emerging concepts in Alzheimer's disease[J]. Annu Rev Pathol, 2015, 10: 291-319. [19] Thal D R, Capetillo-Zarate E, Del Tredici K, et al. The development of amyloid beta protein deposits in the aged brain[J]. Sci Aging Knowledge Environ, 2006, 2006(6): re1. [20] Thal D R, Rüb U, Orantes M, et al. Phases of a beta-deposition in the human brain and its relevance for the development of AD[J]. Neurology, 2002, 58(12): 1791-1800. [21] Braak H, Thal D R, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years[J]. J Neuropathol Exp Neurol, 2011, 70(11): 960-969. [22] Dickson D W. The pathogenesis of senile plaques[J]. J Neuropathol Exp Neurol, 1997, 56(4): 321-339. |